DrugDashboards

Propofol

Propofol · PROPOFOL 10 mg/mL · Injection, Emulsion · Intravenous · Hospira, Inc.

NDC 00409-1511-98 · 25 VIAL, SINGLE-DOSE in 1 TRAY / 20 mL in 1 VIAL, SINGLE-DOSE · ANDA · View full market →

The short version

13 companies supply this market — deep enough that no single failure threatens the supply. Put together: this looks like a healthy supply — the boring kind, which is exactly what you want. Historically, drugs in this position went on to a new shortage within 90 days about 0.4% of the time — roughly 3× the typical drug (0.1%).

The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.

Medicare Part D

No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.

How Part D pricing works →

NADAC price per unit

$0$0.1$0.2Sep 2026Sep 2026$0.1709
1 price point · per MLSource: CMS NADAC

Supply fragility

10● Low risk

Some pressure is visible, but not much — here’s everything the score found to count.

  • sterile injectable+10

The score counts pressure that is already visible — fewer makers, shortages, recalls, falling prices. 0 means none of it; 100 means all of it at once. Recomputed daily · as of Sep 3, 2026

90-day shortage risk (model v2)

0.4%chance of a new FDA shortage posting for propofol (injectable) in the next 90 days

sterile injectable · sole-source market

For scale: the typical drug’s chance is about 0.1% — this one is 3× that.

Backtested statistical model over the whole market, not this package alone. Model details →

Is this a "specialty" drug?

There's no legal definition — it meets 1 of 6 public criteria. Why that matters →

  • Part D specialty tier
  • Costs ≥ $950/fill
  • Biologic (BLA)
  • Injectable / infused
  • Orphan-drug exclusivity
  • REMS program

Regulatory

Application
ANDA077908
TE code
AB
Approval date
Mar 17, 2006
Patents / exclusivity
None on file

Shortage history

No FDA shortage reports for this drug or its presentations.

Recalls (this NDC)

  • Class I · TerminatedAug 22, 2022
    Pfizer Inc. — Presence of particulate matter
  • Class I · TerminatedJul 13, 2022
    Pfizer Inc. — Presence of particulate matter: particulate identified as a beetle.
  • Class II · TerminatedDec 23, 2014
    Hospira Inc. — Presence of Particulate Matter: The firm received a complaint of an embedded particulate in the neck of one vial composed primarily of iron.
  • Class I · TerminatedOct 6, 2014
    Hospira Inc. — Temperature Abuse: Products experienced uncontrolled temperature excursions during transit.
  • Class I · TerminatedApr 2, 2014
    Hospira Inc. — Presence of Particulate Matter: A glass defect was found on the interior neck of the vial during a retain sample inspection where the glass vial contained visible embedded metallic particulate and free floating metallic particulates were also found in solution.
  • Class II · TerminatedDec 12, 2013
    Hospira Inc. — Presence of Particulate Matter: Glass defect located on the interior neck of the vial identified glass surface abrasions and visible embedded particulate matter which could result in the potential for small glass flakes or embedded metal particulate to become dislodged into the solution.
  • Class II · TerminatedOct 11, 2013
    Hospira Inc. — Presence of Particulate Matter: Visible particles embedded in the glass identified during a retain sample inspection.
  • Class II · TerminatedAug 14, 2013
    Hospira Inc. — Presence of Particulate Matter: Visible particulate embedded in the glass vial was observed and confirmed in a sample bottle during retain sample inspection.
  • Class II · TerminatedMay 25, 2013
    Hospira Inc. — Presence of Particulate Matter; single visible particulate was identified during a retain sample inspection identified as stainless steel
  • Class II · TerminatedApr 8, 2013
    Hospira Inc. — Presence of Particulate Matter: A single visible particulate was identified during a retain sample inspection.
  • Class II · TerminatedFeb 25, 2013
    Hospira Inc. — Presence of Particulate Matter: Visible particulate embedded in vials was observed and confirmed in a sample bottle during retain inspection.
  • Class II · TerminatedNov 15, 2012
    Hospira Inc. — Presence of Particulate Matter: Visible particulate and particulate embedded in vials were observed during retain inspection.
  • Class II · TerminatedAug 29, 2012
    Hospira Inc. — Presence of Particulate Matter: A single visible particulate was observed and confirmed in sample bottles of the recalled lots during retain inspection.
  • Class II · TerminatedAug 3, 2012
    Hospira Inc. — Presence of Particulate Matter: A single visible particulate was observed and confirmed in a sample bottle during retain inspection.
  • Class II · TerminatedApr 11, 2012
    Hospira, Inc. — Presence of Particulate Matter: A single visible particulate was observed in a retention sample bottles identified as stainless steel

Manufacturers of Propofol (Injection, Emulsion)

LabelerStrengthFirst seenLast seen
Amneal Pharmaceuticals Private LimitedPROPOFOL 10 mg/mLJul 15, 2026Sep 3, 2026
Fresenius Kabi USA, LLCPROPOFOL 10 mg/mLJul 15, 2026Sep 3, 2026
HF Acquisition Co LLC, DBA HealthFirstPROPOFOL 10 mg/mLJul 15, 2026Sep 3, 2026
Hospira, Inc.PROPOFOL 10 mg/mLJul 15, 2026Sep 3, 2026
Meitheal Pharmaceuticals Inc.PROPOFOL 10 mg/mLJul 15, 2026Sep 3, 2026
Avenacy, LLCPROPOFOL 10 mg/mLJul 15, 2026Sep 2, 2026
Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.PROPOFOL 10 mg/mLJul 15, 2026Sep 2, 2026
Sagent PharmaceuticalsPROPOFOL 10 mg/mLJul 15, 2026Sep 2, 2026
Civica, IncPROPOFOL 10 mg/mLJul 15, 2026Aug 31, 2026
Hikma Pharmaceuticals USA Inc.PROPOFOL 10 mg/mLJul 15, 2026Aug 31, 2026
NorthStar Rx LLCPROPOFOL 10 mg/mLJul 15, 2026Aug 31, 2026
Pfizer Laboratories Div Pfizer IncPROPOFOL 10 mg/mLJul 15, 2026Aug 31, 2026
Anthea Pharma Private LimitedPROPOFOL 10 mg/mLJul 18, 2026Aug 29, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "Propofol — NDC 00409-1511-98," retrieved September 3, 2026, https://drugdashboards.com/drug/00409151198.

Free to cite with attribution — see how the data is put together.